Skip to content

    Indo Borax & Ch.

    INDOBORAX
    Chemicals·2 Jun 2026
    Management Summary

    Indo Borax & Chemicals Ltd. delivered strong financial results for Q4 and FY26, driven by new leadership, capacity optimization, and improved product realizations. The company reported significant revenue and profit growth, maintaining healthy margins despite raw material price pressures. Management outlined plans for CAPEX, new product introductions like Boron Oxide, and increased sales of high-margin products like DOT, while also working on a formal dividend policy.

    Highlights

    5
    • Operating revenue for FY26 grew 22.9% to Rs. 215.45 crores, demonstrating strong top-line performance.

    • Net profit for FY26 increased 18% to Rs. 50.27 crores, indicating healthy bottom-line growth.

    • Q4 FY26 operating revenue increased 25.70% to Rs. 63.01 crores, with Q4 PAT up 41.9% to Rs. 14.53 crores, showcasing robust quarterly results.

    • EBITDA and PAT margins for FY26 stood at 21.8% and 20.5% respectively, reflecting improved operational efficiency and better product realizations.

    • The company declared a significant special and final dividend amounting to Rs. 40 per equity share, rewarding shareholders.

    Concerns

    2
    • Challenging geopolitical conditions led to higher raw material prices and pressure on margins for FY26, though management expressed confidence in maintaining margins going forward.

    • An analyst raised a concern regarding 100% pledged promoter shares, which management redirected to investor relations for a specific answer, stating the company itself has zero debt.

    Key financials

    Metrics

    11

    Periods

    2

    Q4 FY26

    6
    • Operating Revenue
      ₹63.01 Cr
      YoY+25.7%
    • EBITDA
      ₹12.82 Cr
      YoY+25.7%
    • EBITDA Margin
      20.4%
    • PAT
      ₹14.53 Cr
      YoY+41.9%
    • PAT Margin
      21.5%

    FY26

    5
    • Operating Revenue
      ₹215.45 Cr
      YoY+22.9%
    • EBITDA
      ₹44.16 Cr
    • EBITDA Margin
      21.8%
    • PAT
      ₹50.27 Cr
      YoY+18.2%
    • EPS
      ₹15.67

    Capital allocation

    4
    high confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Debt

    Debt disclosed

    Dividend

    ₹30/share (special)

    Liquidity

    Cash ₹70 crores

    Other financial assets (FDs) of Rs. 70 crores, with an additional Rs. 130 crores invested in mutual funds for liquidity to support CAPEX expansions.

    Guidance & targets

    8
    CategoryTargetPriority
    Revenue
    Revenue Growth
    20-35%
    Medium
    Revenue
    Revenue Target
    Rs. 250-plus crore
    Medium
    Margin
    EBITDA Percentage Margins
    Maintain or get better
    High
    Volume
    DOT Sales Volume
    1,500 tons
    High
    Product Development
    Boron Oxide First Lot Commercialization
    First lot
    High
    Product Development
    Boron Oxide Peak Revenue Multiple
    2.5x to 3x of Boric Acid price
    Medium
    Capacity
    Boric Acid Capacity Increase
    1,000 tons to 1,500 tons
    Medium
    CAPEX
    Boron Oxide CAPEX Completion
    Complete
    High

    CAPEX Plan Details

    Next quarter
    CurrentStill in discussion, details post board approval
    TargetSpecific CAPEX plans and timelines for capacity expansion and product portfolio broadening

    Why it matters

    Crucial for understanding future growth drivers and capital allocation strategy.

    We also continue to push ahead with our CAPEX plans for the coming year to expand capacity and broaden our product portfolio further. The details of these will be shared post the board approval. These are still in discussion.

    How to verify

    capital_allocation.capex.fy_planned

    Risks & concerns

    3
    RiskSeverity

    Raw material price volatility

    Geopolitical situations led to higher raw material costs, but management believes their sector is less volatile and they have strategies (contracts) to maintain margins.Management acknowledged

    medium

    Market share saturation for Boric Acid

    With almost 50% market share in Boric Acid, growth opportunities will come from Boric Acid I.P. Grade, DOT, and forward integration of new products.Analyst acknowledged

    medium

    Promoter share pledging

    Analyst concern about 100% pledged promoter shares; management stated company has zero debt and redirected to investor relations for specific details.Analyst deflected

    low

    Q&A highlights

    8

    “Boric Acid Technical is something around 15,000 tons, about Boric Acid I.P., about 900 tons, so that comprises about 15,000-plus tons for this year. DOT was 980 tons, and then Boron Oxide and other traded products, everything put together was about 400 tons.”

    Provides a clear breakdown of product-wise sales volumes, indicating Boric Acid Technical as the largest contributor.

    asked by Rahil Desani

    2 min read6 chapters

    Detailed Narrative

    01

    Robust Financial Performance in Q4 and FY26

    Indo Borax & Chemicals Ltd. reported a strong financial close to FY26, with operating revenue growing 22.9% to Rs. 215.45 crores for the full year. Net profit for FY26 increased 18% to Rs. 50.27 crores. The fourth quarter alone saw a 25.70% rise in operating revenue to Rs. 63.01 crores and a 41.9% increase in PAT to Rs. 14.53 crores. The company maintained healthy EBITDA and PAT margins of 21.8% and 20.5% respectively for FY26, reflecting improved operational efficiencies.

    02

    Strategic Transformation and New Leadership

    FY26 marked a significant transformation for Indo Borax with Zenrock Chemicals emerging as the new promoter and a new leadership team taking charge. This team, including MD & CEO Mr. Suresh Kalra, is focused on fiscal discipline, operational excellence, and value creation. The company monetized non-core assets, which contributed to a special dividend of Rs. 30 per equity share, in addition to the 1000% final dividend, totaling Rs. 40 per share for the year.

    03

    Product Portfolio and Market Leadership

    The company holds a leading position in the Indian Boric Acid market with almost 50% market share. Its core products include Boric Acid Technical (~15,000 tons sales), Boric Acid I.P. (~900 tons), and Disodium Octaborate Tetrahydrate (DOT) (~980 tons sales). Indo Borax is the sole manufacturer of IP-grade Boric acid in India. The manufacturing facility in Pithampur has a capacity of 26,000 tons per annum, comprising 20,000 tons of Boric Acid and 6,000 tons of DOT.

    04

    Growth Strategy and Capacity Expansion

    Management aims for 20-35% revenue growth in the coming year, targeting over Rs. 250 crores, driven by increased realizations, operational efficiencies, and new products. While Boric Acid capacity is nearly fully utilized, the company plans to increase DOT sales from 980 tons to 1,500 tons in the coming year, leveraging its 6,000-ton capacity. They are also actively exploring Boron Oxide, with the first lot expected in 3-4 quarters, and plan to introduce more product lines through CAPEX and R&D.

    05

    Raw Material Sourcing and Margin Stability

    The company sources Ulexite Ore from Turkey, South America, and North America and is actively diversifying its supply chain to mitigate geopolitical risks. Management noted that raw material price volatility in their sector is less severe compared to other chemical sectors. They are confident in maintaining current EBITDA margins of 20-21% due to long-term contracts and the ability to pass on price increases to customers within the value chain.

    06

    Capital Allocation and Liquidity Management

    Indo Borax & Chemicals Ltd. maintains a zero-debt position. The company holds approximately Rs. 70 crores in other financial assets (FDs) and has increased its investments by Rs. 130 crores into mutual funds. This liquidity strategy aims to support upcoming CAPEX expansions and new opportunities. CAPEX plans for capacity expansion and product portfolio broadening are currently under discussion, with details expected post board approval.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.